Patients with diabetes who underwent PCI between January 2016 and May 2017. Patients with diabetes taking chronic SGLT2Is preadmission compared with age- and gender-matched patients with diabetes not taking SGLT2Is. Mean follow-up was not reported. Exclusion criteria: not reported. There was no difference in both groups in clinical characteristics (CVRF previous revascularization, HbA1c, LVEF, prior medical treatment), preprocedural analysis (serum creatinine, eGFR, BNP), or procedural characteristics (contrast volume, number of stents, LVEDP). The gene discussed is NPPB; the disease is diabetes mellitus.